Job title: Chief Business Officer
Assaf Oron has served as chief business officer since January 2017. Prior to this position, he served for over a decade at Evogene (NYSE:EVGN), an agriculture biotechnology company which utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. At Evogene, he worked in various roles such as executive vice president of corporate development and executive vice president of strategy and business development. From 2004 to 2006, Mr. Oron served as CEO of ChondroSite Ltd., a biotechnology company that develops engineered tissue products in the field of orthopedics. From 1999 to 2003, Mr. Oron was a senior project manager and strategic consultant at POC Ltd., a leading Israeli management consulting company. Mr. Oron holds an M.Sc. in Biology (bioinformatics) and a B.Sc. in Chemistry and Economics, both from Tel Aviv University.
Phage Therapies Targeting Pathogenic Bacteria in Chronic Indications 1:00 pm
BOLT – a novel phage discovery platform allowing clinical data within 12-18 months Cystic fibrosis – A phase 1b/2a study of BX004 targeting P. Aeruginosa Atopic dermatitis – BX005, a topical phage cocktail targeting S. AureusRead more
day: Day Two – Track A – 1